Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5167134 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10GLACHRM5 | |
| SCHEMBL10378936 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10GLACHRM5 | |
| SCHEMBL13301617 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10GLACHRM5 | |
| SCHEMBL7620877 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10GLACHRM5 | |
| SCHEMBL14409837 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL18686719 | 0.79 | CA2 (0.44) | HSD17B10SAT1SMN1; SMN2TSHRCA2 | |
| SCHEMBL13108239 | 0.79 | TSHR (0.44) | ALDH1A1SAT1TSHRBTN3A1 | |
| SCHEMBL25682828 | 0.77 | SAT1 (0.32) | SAT1 | |
| SCHEMBL16075571 | 0.77 | PLA2G2A (0.37) | ALDH1A1LMNAHSD17B10GLACHRM5 | |
| SCHEMBL14017058 | 0.77 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10GLACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9776960-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9604999-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9458139-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422279-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160152602-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150141465-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-8952171-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140274961-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20080261923-A1 | Alkene Mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20150141465-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20140274961-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20160152602-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20150133430-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBB, HBG1 | ALDH1A1 1152/4885LMNA 692/4885HSD17B10 407/4885 |
| US-20080261923-A1 | Alkene Mimics | PHOSPHO1, PARN, CHAMP1 | ALDH1A1 4597/4885LMNA 1092/4885HSD17B10 3121/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ALDH1A1 1089/4885LMNA 823/4885HSD17B10 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.